Axcelead, A2 Healthcare Unite for Pharma R\&D in Japan

Axcelead, Inc., A2 Healthcare Corporation and another company have formed a partnership. This deal aims to speed up drug research and development in Japan. This partnership combines the strengths of both organizations. It creates a complete support system for drug development, from discovery to manufacturing.

Axcelead works worldwide, focusing on drug discovery services and mRNA contract development and manufacturing (CDMO). Axcelead Drug Discovery Partners, Inc. delivers its drug discovery expertise. (Fujisawa City, Kanagawa) and Axcelead Tokyo West Partners, Inc. (Hino City, Tokyo), both offering pharmaceutical-grade platforms. Additionally, its subsidiary ARCALIS, Inc. Minamisoma City, Fukushima, has Asia-Pacific’s first GMP-compliant API manufacturing facility. It focuses on mRNA vaccines and therapeutics.

A2 Healthcare is a full-service contract research organization (CRO). They provide clinical development solutions for both pharmaceuticals and medical devices. The company has strong life sciences knowledge. It wants to spark innovation and boost health outcomes. In March 2024, A2 Healthcare opened a new office in Boston, USA. This office will act as a global hub for collaboration. The company promotes “J-STEP” (Japan Strategic Teaming & Entry Program). This initiative aims to boost Japan’s drug development ecosystem and fight drug loss.

Also Read: Fujirebio Acquires PSG to Boost Biological Material Supply

Axcelead and A2 Healthcare are partnering to provide a complete framework. This will support the entire R&D lifecycle. It covers drug discovery, non-clinical research, clinical trials, regulatory submissions, and manufacturing. This approach helps academic institutions, biotech startups, and pharmaceutical companies in Japan and around the world.

Axcelead and A2 Healthcare work together to boost innovation. They aim to improve healthcare outcomes. They do this by advancing pharmaceutical R&D in Japan and around the world.